Skip to main content
Cresco Labs Inc. logo

Cresco Labs Inc. — Investor Relations & Filings

Ticker · CRLBF ISIN · CA22587M1068 LEI · 549300NSGBTQRF1IBL30 CSE Manufacturing
Open in API
Filings indexed 386 across all filing types
Latest filing 2022-06-01 Regulatory Filings
Country CA Canada
Listing CSE CRLBF

About Cresco Labs Inc.

https://www.crescolabs.com/

Cresco Labs Inc. is a vertically integrated, multistate operator in the cannabis industry, specializing in the cultivation, manufacturing, distribution, and retail sale of medical and adult-use cannabis products. The company manages a portfolio of proprietary brands, including Cresco Cannabis, High Supply, and Mindys Edibles, offering various formats such as flowers, concentrates, and edibles. Cresco Labs distributes its products wholesale and through its national dispensary network, primarily branded Sunnyside, across the United States and Germany. The company focuses on professionalizing the cannabis experience, maintaining high-quality production standards, and promoting industry responsibility through advocacy and community initiatives.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2022-06-01 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 52-109FV2 Certification of Interim Filings for a venture issuer, Cresco Labs Inc., signed by the CEO. It certifies the review and fair presentation of interim financial statements and interim MD&A for an interim period. The document is a certification letter and does not contain actual financial data or the interim report itself. According to the CERTIFICATION RULE, such officer certifications referencing interim filings should be classified as Regulatory Filings (RNS), not as the interim report (IR). The document length is short (3003 characters), consistent with a certification letter rather than a full report.
2022-05-19 English
52-109FV2 - Certification of interim filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a certification letter by the CFO of Cresco Labs Inc. regarding the review and fair presentation of interim financial statements and interim MD&A for a certain interim period. It is titled as a 'FORM 52-109FV2 CERTIFICATION OF INTERIM FILINGS VENTURE ISSUER BASIC CERTIFICATE' and explicitly states it is a certification of interim filings, not the filings themselves. The document contains no actual financial data or substantive financial analysis but is an officer certification. According to the CERTIFICATION RULE, such documents should be classified as Regulatory Filings (RNS) rather than as the interim report itself (IR). The document length is short (2995 characters), and it is a certification letter, not the interim report or financial statements. Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2022-05-19 English
Interim MD&A - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis of Financial Condition and Results of Operations for the Three Months Ended March 31, 2022 and 2021.' It contains detailed financial analysis, discussion of revenue, gross profit, SG&A expenses, and other financial components for a quarterly period. The text references unaudited condensed interim consolidated financial statements for the three months ended March 31, 2022 and 2021, indicating it is a comprehensive interim financial report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is not a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-19 English
Interim financial statements/report – English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is titled 'UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS' for the three months ended March 31, 2022 and 2021. It contains detailed financial statements including balance sheets, statements of operations, comprehensive loss, changes in shareholders' equity, cash flows, and notes. The presence of actual financial data for a quarterly period and the term 'interim' clearly indicate this is a quarterly or interim financial report. The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-19 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed press release announcing Cresco Labs' first quarter 2022 financial results, including revenue, EBITDA, and other financial highlights. It contains unaudited consolidated financial statements for the three months ended March 31, 2022, and management commentary on the quarter's performance. The document also discusses the expiration of the Hart-Scott-Rodino (HSR) review period related to a proposed acquisition, indicating ongoing M&A activity. The presence of substantive financial data, including income statements and balance sheet items, and the focus on quarterly results indicate this is a comprehensive interim financial report. The document is not merely an announcement of a report or a certification but contains actual financial statements and analysis for a period shorter than a full fiscal year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-05-18 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.